CRISPR Therapeutics AG (CRSP) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
CRSP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CRSP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -6537.0% | -16191.4% | -16569.8% |
| 2024 | -215.0% | -1333.0% | -1046.4% |
| 2023 | 64.8% | -60.1% | -41.5% |
| 2022 | -25186.7% | -154394.7% | -149122.7% |
| 2021 | 88.9% | 40.9% | 41.4% |
Download Data
Export CRSP earnings history in CSV or JSON format
Free sign-in required to download data
CRISPR Therapeutics AG (CRSP) Earnings Overview
As of May 8, 2026, CRISPR Therapeutics AG (CRSP) reported trailing twelve-month net income of -$569M, reflecting -49.1% year-over-year growth. The company earned $-5.92 per diluted share over the past four quarters, with a net profit margin of -16569.8%.
Looking at the long-term picture, CRSP's historical earnings data spans multiple years. The company achieved its highest annual net income of $378M in fiscal 2021.
CRISPR Therapeutics AG is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$160M net income), NTLA (-$413M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), CRSP has comparable earnings metrics. Compare CRSP vs EDIT →
CRSP Earnings vs Peers
Earnings metrics vs comparable public companies
CRSP Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$582M | -58.8% | -$568M | $-6.47 | -16569.8% | -16191.4% |
| 2024 | -$366M | -138.4% | -$467M | $-4.34 | -1046.4% | -1333.0% |
| 2023 | -$154M | +76.4% | -$223M | $-1.94 | -41.5% | -60.1% |
| 2022 | -$650M | -272.2% | -$673M | $-8.36 | -149122.7% | -154394.7% |
| 2021 | $378M | +208.3% | $374M | $4.70 | 41.4% | 40.9% |
| 2020 | -$349M | -621.8% | -$354M | $-5.29 | -48520.9% | -49295.5% |
| 2019 | $67M | +140.5% | $47M | $1.17 | 23.1% | 16.1% |
| 2018 | -$165M | -141.4% | -$159M | $-3.44 | -5281.1% | -5087.8% |
| 2017 | -$68M | -194.6% | -$65M | $-1.71 | -166.7% | -157.7% |
| 2016 | -$23M | +10.2% | -$68M | $-1.89 | -449.3% | -1319.3% |
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRSP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
Is CRSP growing earnings?
CRSP EPS fell to $-5.92, with earnings declining -49.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-569M.
What are CRSP's profit margins?
CRISPR Therapeutics AG net margin is -16569.8%, with operating margin at -16191.4%. Below-average margins reflect competitive or cost pressures.
How consistent are CRSP's earnings?
CRSP earnings data spans 2014-2025. The declining earnings trend is -49.1% YoY. Historical data enables comparison across business cycles.